Meeting
2022 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) as a minimal residual disease (MRD) assessment and recurrence risk in patients undergoing curative intent resection with or without adjuvant chemotherapy in colorectal cancer: A systematic review and meta-analysis.
Authors
Anusha Chidharla
University of Illinois at Peoria, Peoria, IL
Anusha Chidharla , Eliot Rapoport , Kriti Agarwal , Brenda Linares , Sakti Chakrabarti , Anup Kasi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Local-Regional Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3623)
DOI
10.1200/JCO.2022.40.16_suppl.3623
Abstract #
3623
Poster Bd #
416
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
NSAB C-14: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease.
First Author: Mohamed E. Salem
Poster
2021 Gastrointestinal Cancers Symposium
Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC).
First Author: Gayathri Anandappa
Poster
2020 ASCO Virtual Scientific Program
Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC.
First Author: Noelia Tarazona
Poster
2011 ASCO Annual Meeting
The impact of time to adjuvant chemotherapy (AC) on survival in colorectal cancer (CRC): A systematic review and meta-analysis.
First Author: M. Raphael